{"id":4761,"date":"2019-04-16T13:14:30","date_gmt":"2019-04-16T07:44:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4761"},"modified":"2021-07-24T12:57:17","modified_gmt":"2021-07-24T07:27:17","slug":"notizia-nash-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2","title":{"rendered":"Notizia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a08910449cad\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a08910449cad\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2\/#FDA_gives_thumbs-up_to_Balversa\" >FDA gives thumbs-up\nto Balversa<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2\/#Gilead_and_Novo_Nordisk_to_target_NASH_together\" >Gilead and Novo\nNordisk to target NASH together<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2\/#A_new_drug_for_Hepatitis_BD_raises_expectations\" >A new drug for Hepatitis\nB\/D raises expectations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2\/#Good_news_for_people_who_want_to_lose_weight\" >Good news for people\nwho want to lose weight<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_gives_thumbs-up_to_Balversa\"><\/span><strong>FDA gives thumbs-up\nto Balversa<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">The U.S. FDA has granted approval of <strong>Balversa<\/strong> (<g class=\"gr_ gr_5 gr-alert gr_spell gr_inline_cards gr_disable_anim_appear ContextualSpelling\" id=\"5\" data-gr-id=\"5\">erdafitinib<\/g>) to Belgium-based <strong>Janssen Pharmaceutica<\/strong>, for the treatment of <strong>advanced or metastatic <a href=\"https:\/\/www.delveinsight.com\/report-store\/bladder-cancer-market\">bladder cancer<\/a>. <\/strong>This drug is the first ever approved target-specific medication targeting susceptible <strong>FGFR <\/strong>genetic mutations, and for cancer that has progressed during or following prior platinum-containing chemotherapy. FDA granted <strong>Balversa<\/strong> the <strong>Accelerated Approval<\/strong> to make drugs available for serious conditions and to fulfil unmet needs. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gilead_and_Novo_Nordisk_to_target_NASH_together\"><\/span><strong>Gilead and Novo\nNordisk to target NASH together <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Gilead Sciences <\/strong>and <strong>Novo Nordisk A\/S <\/strong>have announced to join hands to fight <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\">Non-Alcoholic S<g class=\"gr_ gr_24 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"24\" data-gr-id=\"24\">teatohepatitis<\/g><\/a><\/strong> (NASH). The collaboration to combine clinical trials of <strong>Novo Nordisk&#8217;s<\/strong> <strong><g class=\"gr_ gr_4 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"4\" data-gr-id=\"4\">semaglutide<\/g><\/strong> (GLP-1 analogue) and <strong>Gilead&#8217;s<\/strong> <strong><g class=\"gr_ gr_5 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling\" id=\"5\" data-gr-id=\"5\">cilofexor<\/g><\/strong> (FXR agonist) and <strong><g class=\"gr_ gr_6 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling\" id=\"6\" data-gr-id=\"6\">firsocostat<\/g><\/strong> (ACC inhibitor) to treat patients suffering from NASH and advance the understanding of the disease. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"A_new_drug_for_Hepatitis_BD_raises_expectations\"><\/span><strong>A new drug for Hepatitis\nB\/D raises expectations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"> <br><strong>Myr Pharma-<\/strong>a German pharmaceutical company has reported positive results in phase 2b trial of <strong>Bulevirtide<\/strong> to treat chronic <strong>hepatitis B and D<\/strong>. Also known as<strong> Myrcludex<\/strong> <strong>B, <\/strong>it is a novel drug candidate for the treatment of chronic hepatitis B and chronic <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatitis-d-market\">hepatitis D<\/a><\/strong>, and various other inflammatory and metabolic diseases. The trials show the combination of <strong><g class=\"gr_ gr_4 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling\" id=\"4\" data-gr-id=\"4\">bulevirtide<\/g><\/strong> and <strong>peginterferon-alfa<\/strong> can be a promising treatment for HBV\/HDV coinfection. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Good_news_for_people_who_want_to_lose_weight\"><\/span><strong>Good news for people\nwho want to lose weight <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">In a recent move, the U.S. FDA has approved a novel prescription drug <strong><g class=\"gr_ gr_4 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"4\" data-gr-id=\"4\">Plenity<\/g>, <\/strong>for people who want to get rid of their overweight. Developed by <strong>Gelesis-<\/strong> a Boston-based biotechnology company,<strong> <g class=\"gr_ gr_6 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"6\" data-gr-id=\"6\">Plenity<\/g><\/strong> is a pill- based medical device, for people with body mass index ranging from 25 to 40, which makes people feel full faster thus reducing their appetite. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA gives thumbs-up to Balversa The U.S. FDA has granted approval of Balversa (erdafitinib) to Belgium-based Janssen Pharmaceutica, for the treatment of advanced or metastatic bladder cancer. This drug is the first ever approved target-specific medication targeting susceptible FGFR genetic mutations, and for cancer that has progressed during or following prior platinum-containing chemotherapy. FDA granted [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4765,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[3304,2063,3307,794,3303,3308,1469,877,3302,595],"industry":[17225],"therapeutic_areas":[17240,17231,17228,17278],"class_list":["post-4761","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-balversa","tag-bladder-cancer","tag-gelesis","tag-gilead","tag-myr-pharma","tag-myrcludex-b","tag-nash","tag-novo-nordisk","tag-plenity","tag-usfda","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 16\/04\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Gilead Sciences and Novo Nordisk A\/S have announced to join hands to fight Non-alcoholic steatohepatitis (NASH). The collaboration to combine...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 16\/04\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences and Novo Nordisk A\/S have announced to join hands to fight Non-alcoholic steatohepatitis (NASH). The collaboration to combine...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-16T07:44:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09022634\/My-Post-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 16\/04\/2019 - DelveInsight Business Research","description":"Gilead Sciences and Novo Nordisk A\/S have announced to join hands to fight Non-alcoholic steatohepatitis (NASH). The collaboration to combine...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2","og_locale":"en_US","og_type":"article","og_title":"Notizia 16\/04\/2019 - DelveInsight Business Research","og_description":"Gilead Sciences and Novo Nordisk A\/S have announced to join hands to fight Non-alcoholic steatohepatitis (NASH). The collaboration to combine...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-04-16T07:44:30+00:00","article_modified_time":"2021-07-24T07:27:17+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09022634\/My-Post-3.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2","url":"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2","name":"Notizia 16\/04\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09022634\/My-Post-3.jpg","datePublished":"2019-04-16T07:44:30+00:00","dateModified":"2021-07-24T07:27:17+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gilead Sciences and Novo Nordisk A\/S have announced to join hands to fight Non-alcoholic steatohepatitis (NASH). The collaboration to combine...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-nash-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-nash-2#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09022634\/My-Post-3.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09022634\/My-Post-3.jpg","width":647,"height":345,"caption":"NASH"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09022634\/My-Post-3-300x160.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Balversa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">bladder cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gelesis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myr Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myrcludex B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Plenity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USFDA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Balversa<\/span>","<span class=\"advgb-post-tax-term\">bladder cancer<\/span>","<span class=\"advgb-post-tax-term\">Gelesis<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">Myr Pharma<\/span>","<span class=\"advgb-post-tax-term\">Myrcludex B<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">Plenity<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 16, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 16, 2019 1:14 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"NASH","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4761"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4761\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4765"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4761"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4761"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}